
CDK
Gli inibitori delle chinasi ciclina-dipendenti (CDK) sono composti che bloccano l'attività delle CDK, un gruppo di chinasi proteiche che regolano il ciclo cellulare, la trascrizione e altri processi cellulari. Le CDK vengono attivate legandosi alle cicline e la loro attività è cruciale per la progressione delle cellule attraverso le diverse fasi del ciclo cellulare. Inibire le CDK può bloccare la divisione cellulare, portando all'arresto del ciclo cellulare e all'apoptosi, in particolare nelle cellule tumorali in cui le CDK sono spesso disregolate. Gli inibitori delle CDK sono ampiamente utilizzati nella ricerca sul cancro e hanno un potenziale terapeutico nel trattamento di vari tipi di cancro. Presso CymitQuimica, offriamo una selezione completa di inibitori delle CDK di alta qualità per supportare la tua ricerca sul controllo del ciclo cellulare, sul cancro e sullo sviluppo terapeutico.
Trovati 552 prodotti per "CDK".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColore e forma:SolidPeso molecolare:457.625CDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Formula:C26H42ClN7O4Colore e forma:SolidPeso molecolare:552.12Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Formula:C17H32O4Colore e forma:SolidPeso molecolare:300.43BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Colore e forma:SolidCDK2/4-IN-1
CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.Colore e forma:Odour SolidRibociclib-D6 hydrochloride
Ribociclib-D6 hydrochloride is a deuterated form of Ribociclib hydrochloride (T15730), which is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and has over 1000-fold lower activity against the cyclin B/CDK1 complex.Colore e forma:Odour SolidLSN3106729 hydrochloride
CAS:LSN3106729 hydrochloride, an Abemaciclib metabolite, is a CDK-inhibiting antitumor PROTAC CDK4/6 degrader.Formula:C25H29ClF2N8OColore e forma:SolidPeso molecolare:531.00LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColore e forma:SolidPeso molecolare:573.77KB-0742 hydrochloride
KB-0742 hydrochloride is a potent, selective, and orally active CDK9 inhibitor, with an IC50 of 6 nM for CDK9/cyclin T1. It exhibits over 50 times selectivity towards CDK9/cyclin T1 compared to other CDK kinases. Additionally, KB-0742 hydrochloride demonstrates effective antitumor activity.Cimpuciclib
CAS:Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Formula:C30H35FN8OColore e forma:SolidPeso molecolare:542.663CDK7-IN-1
CAS:CDK7-IN-1, analog of YKL-5-124, inhibits cdk7 with IC50 < 100 nM.Formula:C28H35N7O3Colore e forma:SolidPeso molecolare:517.634Abemaciclib metabolite M18
CAS:Abemaciclib M18 (LSN3106729), a potent CDK inhibitor with antitumor action, used in a PROTAC to degrade CDK4/6.Formula:C25H28F2N8OPurezza:98%Colore e forma:SolidPeso molecolare:494.54HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Formula:C28H29Cl2F3N4O4Colore e forma:SolidPeso molecolare:613.46CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Formula:C24H22FN7O2Colore e forma:SolidPeso molecolare:459.48CDK12-IN-4
CAS:CDK12-IN-4 is a pyrazolotriazine that inhibits CDK12 (IC50: 0.641 μM) with high ATP (2 mM) and spares CDK2/Cyclin E and CDK9/Cyclin T1 (IC50: >20 μM).Formula:C20H20F2N8OColore e forma:SolidPeso molecolare:426.432NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Formula:C46H30ClIrN6O2Colore e forma:SolidPeso molecolare:926.44NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Formula:C40H29ClIrN5OColore e forma:SolidPeso molecolare:823.36Men 10376
CAS:Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.Formula:C57H68N12O10Purezza:98%Colore e forma:SolidPeso molecolare:1081.22YKL-5-124 TFA
CAS:YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Formula:C30H34F3N7O5Colore e forma:SolidPeso molecolare:629.63CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Formula:C22H25ClN8OColore e forma:SolidPeso molecolare:452.95Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);Colore e forma:Odour SolidRef: TM-L8100
1mgPrezzo su richiesta10μL*10mM (DMSO)Prezzo su richiesta20μL*10mM (DMSO)Prezzo su richiesta30μL*10mM (DMSO)Prezzo su richiesta50μL*10mM (DMSO)Prezzo su richiesta100μL*10mM (DMSO)Prezzo su richiesta250μL*10mM (DMSO)Prezzo su richiesta(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Formula:C24H25Cl2F3N4OPurezza:98%Colore e forma:SolidPeso molecolare:513.38CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formula:C24H25FN6O3SColore e forma:SolidPeso molecolare:496.56CDK2-IN-43
CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.Formula:C19H27N7OColore e forma:SolidPeso molecolare:369.464PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formula:C44H52Cl2N10O7Purezza:98%Colore e forma:SolidPeso molecolare:903.85CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Formula:C17H11ClN2OPurezza:98.53%Colore e forma:SoildPeso molecolare:294.73Ref: TM-T64373
1mg52,00€1mL*10mM (DMSO)98,00€5mg102,00€10mg166,00€25mg334,00€50mg537,00€100mg767,00€500mg1.558,00€XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.Formula:C53H67N11O7SPurezza:97.11%Colore e forma:SolidPeso molecolare:1002.23Ref: TM-T13361
1mg110,00€5mg268,00€10mg467,00€1mL*10mM (DMSO)517,00€25mg802,00€50mg1.414,00€100mg2.457,00€CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Formula:C26H29FN6OSColore e forma:SolidPeso molecolare:492.61Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Formula:C110H200N48O25Colore e forma:SolidPeso molecolare:2595.07SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurezza:99.96%Colore e forma:SolidPeso molecolare:238.28CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Colore e forma:SolidPeso molecolare:611.795PROTAC CDK9 degrader-2
CAS:PROTAC CDK9 degrader-2, potent, selective, IC50 17 μM in MCF-7, wogonin-derived, targets CRBN.Formula:C39H36N6O10Purezza:98%Colore e forma:SolidPeso molecolare:748.74CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formula:C43H49N11O7Colore e forma:SolidPeso molecolare:831.92Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Colore e forma:Odour SolidRef: TM-L1600
1mgPrezzo su richiesta10μL*10mM (DMSO)Prezzo su richiesta20μL*10mM (DMSO)Prezzo su richiesta30μL*10mM (DMSO)Prezzo su richiesta50μL*10mM (DMSO)Prezzo su richiesta100μL*10mM (DMSO)Prezzo su richiesta250μL*10mM (DMSO)Prezzo su richiestaFDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Colore e forma:LiquidRef: TM-L1610
1mgPrezzo su richiesta10μL*10mM (DMSO)Prezzo su richiesta20μL*10mM (DMSO)Prezzo su richiesta30μL*10mM (DMSO)Prezzo su richiesta50μL*10mM (DMSO)Prezzo su richiesta100μL*10mM (DMSO)Prezzo su richiesta250μL*10mM (DMSO)Prezzo su richiestaLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Colore e forma:Odour SolidCDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Colore e forma:SolidPeso molecolare:503.177JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formula:C53H69N5O9Purezza:98%Colore e forma:SolidPeso molecolare:920.161CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formula:C32H34FN7O4Colore e forma:SolidPeso molecolare:599.655[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formula:C98H138F3N21O39Purezza:98%Colore e forma:SolidPeso molecolare:2291.25CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Formula:C26H34ClN9OColore e forma:SolidPeso molecolare:524.07CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurezza:99.92%Colore e forma:SolidPeso molecolare:261.34CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Formula:C24H30N6O4SColore e forma:SolidPeso molecolare:498.6CPS2
CAS:CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.Formula:C38H42N12O10S2Colore e forma:SolidPeso molecolare:890.94CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purezza:98%Colore e forma:SolidPeso molecolare:285.32YX0597
YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits the growth of GEAC cells (including radioresistant tumors) and suppresses tumor proliferation, metastasis, and cancer stem cells.Colore e forma:Odour SolidEGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purezza:98%Colore e forma:SolidPeso molecolare:884.99CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Colore e forma:SolidPeso molecolare:513.319CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Colore e forma:Odour Solid

